Learn more about the HAEMATO Group and get to know our Executive Board and Supervisory Board.
Behind HAEMATO’s many years of success is a very special company philosophy and common values that determine our daily actions.
The German population – like the societies of other Western European countries – is ageing. Cancer therapies are becoming increasingly important. HAEMATO’s pharmaceutical activities in the pharmaceuticals sector cover different stages of the value chain (active ingredient trade, generics, innovative and patent-protected branded products, manufacture of medications) for cancer therapies and other chronic diseases.
Growth will be achieved from new and improved therapies with innovative branded products as well as from generics (for active ingredients that expire from patent protection).
Long-term and sustainable
HAEMATO’s investments are long-term and sustainable. They are fundamentally geared to the continuous further development of pharmaceutical activities. Security and return on investment characterise the profile.
Permanent increase in value
An investment in HAEMATO is an investment in growing segments of the German pharmaceutical market. The corporate strategy is hardly susceptible to economic or market fluctuations and can thus achieve a high increase in value.
“WITH LOW-COST PHARMACEUTICALS, WE CONTRIBUTE TO HEALTHCARE SECURITY.”